Phospho-β Catenin (Ser675) Antibody [D16B23]

Catalog No.: F3241

Application: Reactivity: Human, Mouse, Rat

Lane 1: Mouse brain, Lane 2: Mouse liver, Lane 3: SK-N-MC, Lane 4: SK-N-MC (forskolin, 100 uM, 30 min)

当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
WB1:1000 IP1:30 IHC1:1000

Application
WB, IP, IHC

Source
Rabbit Monoclonal Antibody

Reactivity
Human, Mouse, Rat

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Observed MW
85 kDa, 90 kDa, 36 kDa
^*なぜ予測分子量と実際の分子量が異なるのか？下記の原因により、実際の分子量が予測と異なる：タンパク質の翻訳後修飾（リン酸化/糖鎖付加），スプライシングバリアント，イソフォーム，相対的な電荷，ポリマー。

Datasheet & SDS

生物学的記述

Specificity
Phospho-β Catenin (Ser675) Antibody [D16B23] detects endogenous levels of total β Catenin protein only when it is phosphorylated at Ser675.

Clone
D16B23

Synonym(s)
CTNNB; OK/SW-cl.35; PRO2286; CTNNB1; Catenin beta-1; Beta-catenin

Background
Phospho-β-Catenin (Ser675) refers to β-catenin (CTNNB1), an Armadillo repeat protein phosphorylated at Ser675 in its C-terminal transactivation domain by PKA, a modification distinct from the N-terminal degradation sites (Ser33/37/Thr41). β-catenin consists of an N-terminal domain (1–133), 12 central Armadillo repeats (134–670) forming a superhelical groove for E-cadherin and TCF/LEF binding, and a C-terminal domain (671–781) containing the Ser675 PKA/AKT consensus motif, which enhances CBP recruitment. Phosphorylation at Ser675 by PKA inhibits β-catenin ubiquitination independently of the GSK3β destruction complex, stabilizes the cytoplasmic pool, promotes nuclear import, and increases β-catenin’s affinity for TCF/LEF transcription factors and the coactivator CBP/p300, thereby enhancing Wnt target gene expression (such as c-Myc, Cyclin D1, and Axin2). Unlike N-terminal phosphorylation that drives proteasomal degradation, Ser675 phosphorylation sustains Wnt/β-catenin signaling to promote proliferation, stemness, and EMT. Dysregulation of this modification contributes to diseases such as colorectal cancer (often due to APC mutations), hepatocellular carcinoma, and fibrosis via hyperactive Wnt/β-catenin transcriptional activity.

Background

Phospho-β-Catenin (Ser675) refers to β-catenin (CTNNB1), an Armadillo repeat protein phosphorylated at Ser675 in its C-terminal transactivation domain by PKA, a modification distinct from the N-terminal degradation sites (Ser33/37/Thr41). β-catenin consists of an N-terminal domain (1–133), 12 central Armadillo repeats (134–670) forming a superhelical groove for E-cadherin and TCF/LEF binding, and a C-terminal domain (671–781) containing the Ser675 PKA/AKT consensus motif, which enhances CBP recruitment. Phosphorylation at Ser675 by PKA inhibits β-catenin ubiquitination independently of the GSK3β destruction complex, stabilizes the cytoplasmic pool, promotes nuclear import, and increases β-catenin’s affinity for TCF/LEF transcription factors and the coactivator CBP/p300, thereby enhancing Wnt target gene expression (such as c-Myc, Cyclin D1, and Axin2). Unlike N-terminal phosphorylation that drives proteasomal degradation, Ser675 phosphorylation sustains Wnt/β-catenin signaling to promote proliferation, stemness, and EMT. Dysregulation of this modification contributes to diseases such as colorectal cancer (often due to APC mutations), hepatocellular carcinoma, and fibrosis via hyperactive Wnt/β-catenin transcriptional activity.

References
[1] Hino S, et al. Mol Cell Biol. 2005 Oct;25(20):9063-72. [2] Fang D, et al. J Biol Chem. 2007 Apr 13;282(15):11221-9.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%